Skip to main content

Research Repository

Advanced Search

EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update.

Ozen, Seza; Sağ, Erdal; Oton, Teresa; Gül, Ahmet; Sieiro Santos, Cristiana; Bayraktar, Deniz; Proft, Fabian Nikolai; Lachmann, Helen J; Kuemmerle Deschner, Jasmin; Gattorno, Marco; Ayaz, Nuray Aktay; Karadağ, Ömer; Yüce, Sezin; Kivity, Shaye; Georgin-Lavialle, Sophie; Sarkisian, Tamara; Kallinich, Tilmann; Hentgen, Véronique; Prior, Yeliz; Uziel, Yosef; Yardeni, Ziv; Carmona, Loreto

EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update. Thumbnail


Authors

Seza Ozen

Erdal Sağ

Teresa Oton

Ahmet Gül

Cristiana Sieiro Santos

Deniz Bayraktar

Fabian Nikolai Proft

Helen J Lachmann

Jasmin Kuemmerle Deschner

Marco Gattorno

Nuray Aktay Ayaz

Ömer Karadağ

Sezin Yüce

Shaye Kivity

Sophie Georgin-Lavialle

Tamara Sarkisian

Tilmann Kallinich

Véronique Hentgen

Yosef Uziel

Ziv Yardeni

Loreto Carmona



Abstract

Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease despite being a rare disease for many rheumatologists. These evidence-based recommendations update the ones issued in 2016 to account for the recent developments in the field and aim to guide rheumatologists and other health professionals in the treatment and follow-up of patients with FMF. A multidisciplinary panel was assembled, including rheumatologists, internists, paediatricians, a nephrologist, an occupational therapist, a physiotherapist, 2 methodologists, and 2 patient representatives, all from the Eastern Mediterranean area and Europe. Several systematic reviews were performed on the pharmacological treatment of FMF and its complications. The previous recommendations were revised considering the updated evidence, and the new levels of evidence were incorporated. The agreement with the recommendations was obtained through a Delphi survey. The final set comprises 4 overarching principles and 12 recommendations, each presented with its degree of agreement (0-10), level of evidence, and rationale. The degree of agreement was greater than 9/10 in all instances, and the level of evidence improved in most updated statements. Improving adherence is emphasised as an important aspect in several statements. These new recommendations include a priority set, quality indicators, and other suggested implementation strategies. This article presents a set of widely accepted recommendations for treating and monitoring FMF, supported by the best available evidence and expert opinion. These recommendations are valuable for guiding physicians in caring for patients with FMF.

Journal Article Type Article
Acceptance Date Nov 21, 2024
Online Publication Date Apr 9, 2025
Deposit Date May 9, 2025
Publicly Available Date May 9, 2025
Journal Annals of the rheumatic diseases
Print ISSN 0003-4967
Electronic ISSN 1468-2060
Publisher BMJ Publishing Group
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1016/j.ard.2025.01.028